Close Menu
Home » CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients

CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients

Jan 27, 2020
|
staff reporter

NEW YORK – The Centers for Medicare & Medicaid Services on Monday finalized the criteria under which it will grant national coverage to next-generation sequencing tests for assessing inherited cancer risk.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Add the Missing Data

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

Two Red Panda Species

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

Kit Fix

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

Nature Papers Explore Epigenetic Factors in Aging, Gene Loss in Animal Kingdom

In Nature this week: epigenetic factors that prevent healthy aging and more.

What's Popular?

In Reimbursement News

  1. Congressional Caucus Working to Raise Personalized Medicine Awareness Among Legislators

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.